MYL: U.S. FDA Approves Mylan and Biocon's Ogivri(TM), the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

New alert via PocketInfo for MYL:

U.S. FDA Approves Mylan and Biocon's Ogivri(TM), the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

Press Releases: http://investor.mylan.com/releases.cfm
SEC Filings: http://investor.mylan.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8